Belzutifan for patients with Von Hippel-Lindau (VHL) disease-associated heterogeneous tumors – a retrospective single center analysis

Abstract Background Von Hippel-Lindau (VHL) disease is a hereditary tumor predisposition syndrome characterized by benign and malignant tumors affecting multiple organ systems. Standard treatment primarily involves surgical resection and tumor ablation, which can lead to progressive organ dysfunctio...

Description complète

Détails bibliographiques

Auteurs principaux:	Kilian Rhein, Fruzsina Kotsis, Athina Ganner, Sophie Astheimer, Christine Julia Gizaw, Yannik Laich, Cordula Annette Jilg, Jan-Helge Klingler, Elke Neumann-Haefelin
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2025-11-01
Collection:	BMC Cancer
Sujets:	Von Hippel-Lindau disease Belzutifan HIF-2α inhibitor Renal cell carcinoma Hemangioblastoma Neuroendocrine tumors
Accès en ligne:	https://doi.org/10.1186/s12885-025-15192-8
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!